KBC Securities - ONWARD MEDICAL NV (ONWD) Onward Medical New ARC-EX study published

Report

KBC Securities

Thomas Vranken

Onward Medical New ARC-EX study published

Spinal Research UK published the results of a new study with Onward's non-invasive ARC-EX device. Ten patients received 120 sessions of ARC-EX + rehab, showing statistically significant improvements on various endpoints for functional recovery. Improvements did not plateau after 1 year, underlining ARC-EX' game changing potential, we reiterate Buy/€10.4 TP.

25/02/2025 1 EN

Underlying

ONWARD MEDICAL NV

See profile

NL0015000HT4 Euronext Brussels Netherlands

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

KBC Securities

Morning Notes : AKZA NA, ASML NA, HYL BB, DEME BB, ONWD BB

: AKZA NA, ASML NA, HYL BB, DEME BB, ONWD BB

11h / 42m 11h / 42m 1 EN

GlobeNewsWire

ONWARD Medical Announces Publication of One-Year Study Showing Benefit of Sustained Access to ARC-EX Therapy

ONWARD Medical Announces Publication of One-Year Study Showing Benefit of Sustained Access to ARC-EX Therapy Study shows significant functional improvements after one year of ARC-EX Therapy Improvements were observed throughout one-year treatment period with no plateau Results demonstrate the importance of sustained access to ARC-EX Therapy EINDHOVEN, the Netherlands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with s...

13h / 8m 13h / 8m 1 EN

Morning Notes : AKZA NA, ASML NA, HYL BB, DEME BB, ONWD BB

: AKZA NA, ASML NA, HYL BB, DEME BB, ONWD BB

11h / 42m 11h / 42m 1 EN

Jacob Mekhael ... (+2)

Jacob Mekhael
Thomas Vranken

Hyloris FIRST LOOK: New pipeline addition with RedHill & valacyclovir PDUFA set

Hyloris announced a new licensing agreement with RedHill Biopharma to bring in ex-US rights for ondansetron ER, a serotonin blocker that provides relief from nausea and vomiting with chemotherapy, radiotherapy and post-operative recovery. Meanwhile, the FDA accepted oral liquid valacyclovir's regulatory submission for review with a PDUFA date set for October 12, 2025. We intend to incorporate ondansetron ER in a future update of our model and look forward to the valacyclovir decision, while reiterating our Hold rating and € 5 TP.

11h / 58m 11h / 58m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Onward Medical New ARC-EX study published

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : AKZA NA, ASML NA, HYL BB, DEME BB, ONWD BB

ONWARD Medical Announces Publication of One-Year Study Showing Benefit of Sustained Access to ARC-EX Therapy

Morning Notes : AKZA NA, ASML NA, HYL BB, DEME BB, ONWD BB

Hyloris FIRST LOOK: New pipeline addition with RedHill & valacyclovir PDUFA set

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe